Growth ConcernsShares have been weak due to communication and disclosure issues, concerns about Enfusion's ability to accelerate growth, and flat sequential net new ARR trends.
Investor ConcernsThe stock is down 30% over the last 6 months, which is largely attributed to investor concerns regarding the quality of acquired assets and Clearwater’s progress on integration of multiple inorganic pieces of business at the same time.
Revenue Growth OutlookThe company did not explicitly reiterate its 20% year-over-year medium-term revenue growth outlook, with Enfusion likely being the main source of drag.